Organ preservation with radiochemotherapy in locally advanced bladder cancer
Ausili-Cefaro, G.; Marmiroli, L.; Fiorentino, G.; Nardone, L.; Palazzoni, G.; Salvi, G.
Rays 22(3): 460-466
1997
ISSN/ISBN: 0390-7740 PMID: 9446951 Document Number: 475482
Bladder cancer is frequent in Western countries and predominantly affects males (ratio: 3:1). In 15-25% of cases there is muscular wall invasion. Treatment of > T1 tumors is radical cystectomy with or without preoperative radiotherapy. In T2 there is 60% survival at 5 years, 40% in T3. Exclusive radiotherapy used to prevent radical cystectomy has lower survival rates in T2 (30-40% at 5 years) as well as in T3 (20% at 5 years). Recently, concomitant radiotherapy and chemotherapy has been introduced again to prevent demolitive surgery. Results are similar or slightly superior than those of surgery alone. In our experience with radiotherapy 180 cGy daily for a total dose of 64 Gy in combination with fluorouracil in locally advanced tumors 40% bladder preservation was achieved.